Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis
- 1 March 2016
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (3), 1667-1675
- https://doi.org/10.1128/aac.02793-15
Abstract
Intravaginal rings releasing tenofovir (TFV) or its prodrug, tenofovir disoproxil fumarate (TDF), are being evaluated for HIV and herpes simplex virus (HSV) prevention. The current studies were designed to determine the mechanisms of drug accumulation in human vaginal and immune cells. The exposure of vaginal epithelial or T cells to equimolar concentrations of radiolabeled TDF resulted in over 10-fold higher intracellular drug levels than exposure to TFV. Permeability studies demonstrated that TDF, but not TFV, entered cells by passive diffusion. TDF uptake was energy independent but its accumulation followed nonlinear kinetics, and excess unlabeled TDF inhibited radiolabeled TDF uptake in competition studies. The carboxylesterase inhibitor bis-nitrophenyl phosphate reduced TDF uptake, suggesting saturability of intracellular carboxylesterases. In contrast, although TFV uptake was energy dependent, no competition between unlabeled and radiolabeled TFV was observed, and the previously identified transporters, organic anion transporters (OATs) 1 and 3, were not expressed in human vaginal or T cells. The intracellular accumulation of TFV was reduced by the addition of endocytosis inhibitors, and this resulted in the loss of TFV antiviral activity. Kinetics of drug transport and metabolism were monitored by quantifying the parent drugs and their metabolites by high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS). Results were consistent with the identified mechanisms of transport, and the exposure of vaginal epithelial cells to equimolar concentrations of TDF compared to TFV resulted in ∼40-fold higher levels of the active metabolite, tenofovir diphosphate. Together, these findings indicate that substantially lower concentrations of TDF than TFV are needed to protect cells from HIV and HSV-2.Keywords
Funding Information
- HHS | National Institutes of Health (U19AI03461)
This publication has 47 references indexed in Scilit:
- Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 TransmissionScience Translational Medicine, 2011
- Topical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 ReplicationCell Host & Microbe, 2011
- Topical Prophylaxis for HIV Prevention in Women: Becoming a RealityCurrent HIV/AIDS Reports, 2011
- Tenofovir renal proximal tubular toxicity is regulated By OAT1 and MRP4 transportersLaboratory Investigation, 2011
- Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and TenofovirAntimicrobial Agents and Chemotherapy, 2011
- A Randomized Trial to Assess Anti-HIV Activity in Female Genital Tract Secretions and Soluble Mucosal Immunity Following Application of 1% Tenofovir GelPLOS ONE, 2011
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in WomenScience, 2010
- A Differential Role for Macropinocytosis in Mediating Entry of the Two Forms of Vaccinia Virus into Dendritic CellsPLoS Pathogens, 2010
- Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac1 and Cdc42 signalingThe Journal of cell biology, 2010
- Intracellular ‘boosting’ of darunavir using known transport inhibitors in primary PBMCBritish Journal of Clinical Pharmacology, 2009